Tiludronic acid

CLINICAL USE

Paget’s disease of bone

DOSE IN NORMAL RENAL FUNCTION

400 mg daily for 12 weeks

PHARMACOKINETICS

Molecular weight : 318.6

%Protein binding : 91

%Excreted unchanged in urine : 60

Volume of distribution (L/kg) : No data

half-life – normal/ESRD (hrs) : >100/205

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

60–90 Use with caution 30–60 Use with caution <30 Avoid

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD : Unlikely to be dialysed. Avoid

HD : Unlikely to be dialysed. Avoid

HDF/high flux : Unknown dialysability. Avoid

CAV/VVHD : Unlikely to be dialysed. Avoid

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs Calcium salts: reduced absorption

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Take as a single dose with a glass of water at least 2 hours before or after meals, calcium supplements or aluminium or magnesium containing antacids Patients should ensure their calcium and vitamin D intake is adequate Calcium metabolism disorders should be corrected before starting therapy Bisphosphonates are mainly eliminated by excretion of unchanged drug in the urine .

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home